Inflammatory Diseases
Harnessing uracil-DNA biology to advance treatment for inflammatory diseases
CV6 is applying its expertise in nucleotide metabolism and the Genomic Uracil Stress Response (GUSR) to develop new therapeutic approaches for inflammatory diseases.
Our lead preclinical candidate, CV6-1271, is being developed for rheumatoid arthritis, including in combination with methotrexate. In preclinical arthritis models, CV6-1271 demonstrated activity alone and enhanced the response to methotrexate.
These findings support the development of uracil-DNA biology as a therapeutic approach beyond oncology. Our goal is to deliver meaningful advances for patients whose disease remains inadequately controlled by established treatment.
CV6-1271
CV6-1271 is in preclinical development for rheumatoid arthritis.
In arthritis models, it showed activity on its own and strengthened the response to methotrexate. No additional toxicity was observed under the conditions tested.
These findings support further development toward clinical evaluation.